These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16514718)

  • 1. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
    [No Abstract]   [Full Text] [Related]  

  • 2. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov; 145(46):47. PubMed ID: 14699834
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B; Hanania NA; ZuWallack R; Kalberg C; Emmett A; Brown CP; Knobil K
    Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
    [No Abstract]   [Full Text] [Related]  

  • 10. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
    Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined salmeterol and fluticasone for COPD.
    Vassiliou V
    Lancet; 2003 May; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract]   [Full Text] [Related]  

  • 16. Does low-dose seretide reverse chronic obstructive pulmonary disease and are the benefits sustained over time? An open-label Swedish crossover cohort study between 1999 and 2005.
    Rustscheff S; Rydén L
    J Asthma; 2010 Mar; 47(2):214-6. PubMed ID: 20170332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.
    Vestbo J; Anderson JA; Calverley PM; Celli B; Ferguson GT; Jenkins C; Yates JC; Jones PW
    Clin Respir J; 2011 Jan; 5(1):44-9. PubMed ID: 21159140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M; Agusti AG; Barnes NC
    COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
    Niewoehner DE
    COPD; 2009 Feb; 6(1):1-3. PubMed ID: 19229702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.